Ponte Biosciences

Executive Summary

Ponte Biosciences is a preclinical-stage biotherapeutic company developing the Spheroid Reservoir Bioartificial Liver (SRBAL) System, a cell-based therapy designed to treat acute liver failure. The SRBAL utilizes metabolically active primary human hepatocytes to temporarily replace or supplement liver function in ICU patients, addressing the critical shortage of donor organs and the lack of effective bridging therapies. Founded in 2020 and headquartered in San Diego, Ponte aims to establish a scalable, high-quality source of human hepatocytes for both therapeutic and research applications. With acute liver failure carrying high mortality and limited treatment options, Ponte's technology has the potential to significantly improve patient outcomes. However, as a preclinical entity, the company faces substantial development risks and capital requirements. Key upcoming milestones include IND-enabling studies, potential partnership discussions, and preparation for clinical trials, which could drive value inflection points.

Upcoming Catalysts (preview)

• Q4 2026IND Submission for SRBAL System35% success
• Q2 2026Series A Financing Round50% success
• Q3 2026Presentation of Preclinical Efficacy Data70% success